Developer docs
API playgroundTry for free, no card

Search company profiles

Cancer Commons

Full company profile

uuid000behe

Namestring
Cancer Commons
Legal namestring
Cancer Commons
Company typeenum
Private
Founded yearint
2011
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
personalized cancer treatment, oncology clinical research, cancer patient navigation, precision oncology services, molecular profiling analysis
Industry4 codes
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLACABAI
Clinical Document & Data Exchange (C-CDA, CCD, Direct Messaging)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
SECONDARYHLALAFAD
Oncology Remote Symptom Monitoring & Care Navigation
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Misc Health & Allied Services, Nec8090
  • Services-Health Services8000
Product category
Oncology Patient Navigation Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Philanthropic Donations
TypeGrants Donations
Description

Cancer Commons is a 501(c)(3) nonprofit that provides all services free to patients, funded entirely through charitable donations. The organization states that every donation of $2,000 or more offers expert guidance to a patient. Tax Identification Number: 45-3266802.

cancercommons.org
2Clinical Study Participation
TypeGrants Donations
Description

The CCCS001 observational study provides scientific analysis at no charge to participants. While Cancer Commons guidance is free, costs for Drug Sensitivity Tests and treatments may be covered through insurance, compassionate use programs, or other pathways.

cancercommons.org
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details1 tier
1Free Expert Guidance for All Patients
ModelFreemiumBilling cadenceMonthly
Notes

All Cancer Commons services including precision treatment matching, clinical trial exploration, strategic treatment planning, knowledge translation, emotional support, and access & equity assistance are provided at no cost to patients. Funded through philanthropy.

cancercommons.org
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Cancer Commons is a 501(c)(3) nonprofit that provides free, PhD-level personalized treatment guidance to advanced/metastatic cancer patients who have exhausted standard-of-care options. Its core service pairs oncology nurses and clinical scientists who analyze tumor molecular profiles to recommend off-guideline FDA-approved drugs and clinical trials, delivered as a Scientific Evidence Report to the patient's own oncologist. The CCCS001 N-of-1 observational clinical study is the flagship research initiative supporting this guidance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 10,000+ patients helped at no cost
+3 more records
Product overview1 text field

Cancer Commons offers a unified service portfolio centered on Expert Guidance as the core offering—a personalized cancer treatment navigation service staffed by oncology nurses and PhD-level clinical scientists who analyze patient profiles to recommend actionable treatment plans. The CCCS001 Clinical Study (NCT07343024) is the flagship research initiative, an N-of-1 observational study that pairs patients with diagnostic testing (genomic profiling and drug sensitivity tests) to identify FDA-approved off-guideline treatment options. The study produces a Scientific Evidence Report as a key deliverable. Supporting offerings include Patient Stories (documented case studies) and Research News (expert-curated cancer research content). All services are provided free of charge to patients, funded through philanthropy.

Product and service3 records
1Expert Guidance
CategoryOncology Patient Navigation Service
Description

Personalized cancer treatment navigation service that combines oncology nurses and PhD-level clinical scientists to analyze each patient's unique tumor molecular profile and treatment history, producing customized action plans for advanced cancer patients who have exhausted standard treatment options. The service identifies precision treatment matches, off-guideline FDA-approved drugs, clinical trial opportunities, and strategic treatment sequencing. All guidance is provided free to patients.

2CCCS001 Clinical Study
CategoryClinical Research Study
Description

N-of-1 Observational Clinical Study (NCT07343024) that uses advanced diagnostic tests including genomic profiling and Drug Sensitivity Tests to identify FDA-approved off-guideline drugs for advanced cancer patients. The site-less study enables participation through any oncologist nationwide with no travel required and produces a Scientific Evidence Report identifying promising treatment options.

3Scientific Evidence Report
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

xCures is listed as a partner organization. Cancer Commons collaborates with xCures on initiatives that may benefit patients. Mika Newton, CEO of xCures, serves as a Distinguished Advisor to Cancer Commons.

2Tempus
Strategic tierCoreTypeTechnology or Integration
Description

Tempus is listed as a partner organization. Tempus provides genomic testing services that may be used by Cancer Commons patients for molecular profiling.

cancercommons.org
3H8 Cancer
Strategic tierMinorTypeStrategic or Co-development Partner
Description

H8 Cancer is listed as a partner organization supporting Cancer Commons mission.

cancercommons.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pancreatic Cancer Action Network is listed as a partner organization, providing referral channel for pancreatic cancer patients seeking additional treatment options.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Musella Foundation operates a patient navigation program in partnership with Cancer Commons and Head For The Cure. Al Musella, DPM serves as a Distinguished Advisor to Cancer Commons. The foundation supports brain tumor research and patient information.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

POETIC (Precision Oncology for Emerging Tumors Early-phase Immunotherapy Consortium) is listed as a partner organization.

Strategic tierCoreTypeTechnology or Integration
Description

Travera provides cancer therapy selection tests that Cancer Commons utilizes. CEO Clifford Reid, PhD formerly co-founded Travera and serves as current CEO of Cancer Commons.

8Brain Cancer Support and Solutions Alliance (BCSSA)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

BCSSA has launched a dedicated nurse navigator program in partnership with Cancer Commons to provide comprehensive patient and caregiver assistance for brain cancer patients.

cancercommons.org
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

xCures is an AI-driven precision oncology platform that aggregates patient molecular and outcomes data to recommend individualized treatments for advanced cancer patients. It is directly comparable to Cancer Commons as both deliver off-guideline and clinical-trial treatment recommendations using patient data, and xCures is even listed as a Cancer Commons partner with its CEO serving as a Distinguished Advisor.

2Tempus
TypeBroad incumbent
Description

Tempus is a large precision medicine company offering genomic sequencing, AI-enabled clinical decision support, and clinical trial matching across oncology. It is a Cancer Commons partner for genomic testing and broadly comparable as a precision oncology intelligence platform, though it operates at much greater scale across many disease areas.

TypeBroad incumbent
Description

Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling of tumors to inform treatment selection and clinical trial enrollment in oncology. It overlaps with Cancer Commons' molecular profiling and treatment-matching work, but operates at population scale as part of a broader diagnostics and pharma-services portfolio.

TypeBroad incumbent
Description

Guardant Health specializes in liquid biopsy and genomic profiling for advanced cancer, supporting therapy selection and disease monitoring. It is comparable to Cancer Commons in the oncology molecular diagnostics and treatment-matching domain, but with a much broader commercial footprint and FDA-approved tests.

TypeBroad incumbent
Description

Caris offers molecular profiling (DNA, RNA, protein) and AI-driven precision oncology solutions to match patients with therapies and trials. It overlaps with Cancer Commons on tumor profiling and treatment recommendations, but operates as a full-service commercial diagnostics company serving oncologists across the US and internationally.

6Perthera
TypeDirect peer
Description

Perthera provides AI-enabled precision oncology treatment recommendations and molecular tumor board reviews for advanced cancer patients. It is a direct peer to Cancer Commons in matching off-guideline therapies and trials to molecular profiles, with a similar focus on patients who have exhausted standard options.

TypeDirect peer
Description

Massive Bio uses AI to match cancer patients with clinical trials and precision treatments. It is closely comparable to Cancer Commons' clinical trial exploration and treatment-matching services for advanced cancer patients, with a similar provider- and patient-facing workflow.

8Mendel.ai
TypeEmerging player
Description

Mendel.ai applies large language models to structured and unstructured clinical data to match oncology patients to clinical trials. It overlaps with Cancer Commons' clinical trial exploration service but focuses specifically on automated trial matching rather than full treatment recommendation.

9Deep 6 AI
TypeEmerging player
Description

Deep 6 AI uses AI to mine EHR data for clinical trial recruitment and cohort identification across therapeutic areas including oncology. It is thematically comparable to Cancer Commons' clinical trial matching capability, though Deep 6 primarily sells to sponsors and health systems rather than directly to patients.

TypeOthers
Description

Travera provides a drug sensitivity test that measures cancer cell responses to approved drugs. It is a Cancer Commons technology partner and directly comparable on the diagnostic side of Cancer Commons' CCCS001 study, though Travera operates as an upstream testing vendor rather than a full navigation service.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cancer Commons

Oncology Patient Navigation Servicescancercommons.org

Cancer Commons firmographics

Firmographics
Name
Cancer Commons
Legal name
Cancer Commons
Website
https://cancercommons.org
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Cancer Commons industry classification

Industry
Product category
Oncology Patient Navigation Services
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Misc Health & Allied Services, Nec (8090), Services-Health Services (8000)
akta.pro industry
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLACABAI
Clinical Document & Data Exchange (C-CDA, CCD, Direct Messaging)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
SECONDARYHLALAFAD
Oncology Remote Symptom Monitoring & Care Navigation
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Personalized cancer treatment
  • Oncology clinical research
  • Cancer patient navigation
  • Precision oncology services
  • Molecular profiling analysis

Where Cancer Commons is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cancer Commons business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Philanthropic Donations: Cancer Commons is a 501(c)(3) nonprofit that provides all services free to patients, funded entirely through charitable donations. The organization states that every donation of $2,000 or more offers expert guidance to a patient. Tax Identification Number: 45-3266802.
  2. Clinical Study Participation: The CCCS001 observational study provides scientific analysis at no charge to participants. While Cancer Commons guidance is free, costs for Drug Sensitivity Tests and treatments may be covered through insurance, compassionate use programs, or other pathways.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyFree Expert Guidance for All Patients

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Cancer Commons product offering

Product offering

Core offering

Cancer Commons is a 501(c)(3) nonprofit that provides free, PhD-level personalized treatment guidance to advanced/metastatic cancer patients who have exhausted standard-of-care options. Its core service pairs oncology nurses and clinical scientists who analyze tumor molecular profiles to recommend off-guideline FDA-approved drugs and clinical trials, delivered as a Scientific Evidence Report to the patient's own oncologist. The CCCS001 N-of-1 observational clinical study is the flagship research initiative supporting this guidance.

Product overview

Cancer Commons offers a unified service portfolio centered on Expert Guidance as the core offering—a personalized cancer treatment navigation service staffed by oncology nurses and PhD-level clinical scientists who analyze patient profiles to recommend actionable treatment plans. The CCCS001 Clinical Study (NCT07343024) is the flagship research initiative, an N-of-1 observational study that pairs patients with diagnostic testing (genomic profiling and drug sensitivity tests) to identify FDA-approved off-guideline treatment options. The study produces a Scientific Evidence Report as a key deliverable. Supporting offerings include Patient Stories (documented case studies) and Research News (expert-curated cancer research content). All services are provided free of charge to patients, funded through philanthropy.

Differentiator

Problem solved

Functional benefit

Products and services

  • Expert Guidance Personalized cancer treatment navigation service that combines oncology nurses and PhD-level clinical scientists to analyze each patient's unique tumor molecular profile and treatment history, producing customized action plans for advanced cancer patients who have exhausted standard treatment options. The service identifies precision treatment matches, off-guideline FDA-approved drugs, clinical trial opportunities, and strategic treatment sequencing. All guidance is provided free to patients.
  • CCCS001 Clinical Study N-of-1 Observational Clinical Study (NCT07343024) that uses advanced diagnostic tests including genomic profiling and Drug Sensitivity Tests to identify FDA-approved off-guideline drugs for advanced cancer patients. The site-less study enables participation through any oncologist nationwide with no travel required and produces a Scientific Evidence Report identifying promising treatment options.
  • Scientific Evidence Report

Quantifiable outcome

  • 10,000+ patients helped at no cost
  • +3 more outcomes

Companies that use Cancer Commons

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Cancer Commons technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cancer Commons partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • xCurescoreStrategic or Co-development PartnerxCures is listed as a partner organization. Cancer Commons collaborates with xCures on initiatives that may benefit patients. Mika Newton, CEO of xCures, serves as a Distinguished Advisor to Cancer Commons.
  • TempuscoreTechnology or IntegrationTempus is listed as a partner organization. Tempus provides genomic testing services that may be used by Cancer Commons patients for molecular profiling.
  • H8 CancerminorStrategic or Co-development PartnerH8 Cancer is listed as a partner organization supporting Cancer Commons mission.
  • Pancreatic Cancer Action Network (Pancan)coreStrategic or Co-development PartnerPancreatic Cancer Action Network is listed as a partner organization, providing referral channel for pancreatic cancer patients seeking additional treatment options.
  • Musella Foundation for Brain Tumor Research & InformationcoreStrategic or Co-development PartnerThe Musella Foundation operates a patient navigation program in partnership with Cancer Commons and Head For The Cure. Al Musella, DPM serves as a Distinguished Advisor to Cancer Commons. The foundation supports brain tumor research and patient information.
  • Poetic (POETIC Phase 1)minorStrategic or Co-development PartnerPOETIC (Precision Oncology for Emerging Tumors Early-phase Immunotherapy Consortium) is listed as a partner organization.
  • TraveracoreTechnology or IntegrationTravera provides cancer therapy selection tests that Cancer Commons utilizes. CEO Clifford Reid, PhD formerly co-founded Travera and serves as current CEO of Cancer Commons.
  • Brain Cancer Support and Solutions Alliance (BCSSA)minorStrategic or Co-development PartnerBCSSA has launched a dedicated nurse navigator program in partnership with Cancer Commons to provide comprehensive patient and caregiver assistance for brain cancer patients.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Cancer Commons competitors and assessment

Company assessment

Direct peers

  • xCures: xCures is an AI-driven precision oncology platform that aggregates patient molecular and outcomes data to recommend individualized treatments for advanced cancer patients. It is directly comparable to Cancer Commons as both deliver off-guideline and clinical-trial treatment recommendations using patient data, and xCures is even listed as a Cancer Commons partner with its CEO serving as a Distinguished Advisor.
  • Perthera: Perthera provides AI-enabled precision oncology treatment recommendations and molecular tumor board reviews for advanced cancer patients. It is a direct peer to Cancer Commons in matching off-guideline therapies and trials to molecular profiles, with a similar focus on patients who have exhausted standard options.
  • Massive Bio: Massive Bio uses AI to match cancer patients with clinical trials and precision treatments. It is closely comparable to Cancer Commons' clinical trial exploration and treatment-matching services for advanced cancer patients, with a similar provider- and patient-facing workflow.

Broad incumbents

  • Tempus: Tempus is a large precision medicine company offering genomic sequencing, AI-enabled clinical decision support, and clinical trial matching across oncology. It is a Cancer Commons partner for genomic testing and broadly comparable as a precision oncology intelligence platform, though it operates at much greater scale across many disease areas.
  • Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling of tumors to inform treatment selection and clinical trial enrollment in oncology. It overlaps with Cancer Commons' molecular profiling and treatment-matching work, but operates at population scale as part of a broader diagnostics and pharma-services portfolio.
  • Guardant Health: Guardant Health specializes in liquid biopsy and genomic profiling for advanced cancer, supporting therapy selection and disease monitoring. It is comparable to Cancer Commons in the oncology molecular diagnostics and treatment-matching domain, but with a much broader commercial footprint and FDA-approved tests.
  • Caris Life Sciences: Caris offers molecular profiling (DNA, RNA, protein) and AI-driven precision oncology solutions to match patients with therapies and trials. It overlaps with Cancer Commons on tumor profiling and treatment recommendations, but operates as a full-service commercial diagnostics company serving oncologists across the US and internationally.

Emerging players

  • Mendel.ai: Mendel.ai applies large language models to structured and unstructured clinical data to match oncology patients to clinical trials. It overlaps with Cancer Commons' clinical trial exploration service but focuses specifically on automated trial matching rather than full treatment recommendation.
  • Deep 6 AI: Deep 6 AI uses AI to mine EHR data for clinical trial recruitment and cohort identification across therapeutic areas including oncology. It is thematically comparable to Cancer Commons' clinical trial matching capability, though Deep 6 primarily sells to sponsors and health systems rather than directly to patients.

Others

  • Travera: Travera provides a drug sensitivity test that measures cancer cell responses to approved drugs. It is a Cancer Commons technology partner and directly comparable on the diagnostic side of Cancer Commons' CCCS001 study, though Travera operates as an upstream testing vendor rather than a full navigation service.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Cancer Commons social profiles

Digital presence

Cancer Commons compliance and trust

Trust signal

Compliance1 record

Cancer Commons financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cancer Commons leadership team

Management profile

Number of profiles

Profiles9 records

Cancer Commons funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cancer Commons M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancer Commons

What does Cancer Commons do?

Cancer Commons is a 501(c)(3) nonprofit that provides free, PhD-level personalized treatment guidance to advanced/metastatic cancer patients who have exhausted standard-of-care options. Its core service pairs oncology nurses and clinical scientists who analyze tumor molecular profiles to recommend off-guideline FDA-approved drugs and clinical trials, delivered as a Scientific Evidence Report to the patient's own oncologist. The CCCS001 N-of-1 observational clinical study is the flagship research initiative supporting this guidance.

Is Cancer Commons a public or private company?

Cancer Commons is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Cancer Commons founded?

Cancer Commons was founded in 2011. It employs 11 to 50 people.

Where is Cancer Commons based?

Cancer Commons is headquartered in Mountain View, United States, in the North America region.

How does Cancer Commons make money?

Two revenue lines are on record. Philanthropic Donations are the primary driver. The others are clinical Study Participation.

Who are Cancer Commons's main competitors?

Direct peers on record are xCures, Perthera and Massive Bio. Broad incumbents are Tempus, Foundation Medicine, Guardant Health and Caris Life Sciences. Emerging players are Mendel.ai and Deep 6 AI. Travera is listed as an others.

Does Cancer Commons have an API?

No public API is recorded for Cancer Commons.

What industry is Cancer Commons in?

Cancer Commons's product category is Oncology Patient Navigation Services. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 5417 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireCancer Commons Opens Enrollment in its N-of-1 Clinical StudyCancer Commons has opened enrollment for its N-of-1 Observational Clinical Study (CCCS001), which uses genomic tests and drug sensitivity tests to identify personalized, off-guideline cancer treatments for patients who have exhausted standard options. The study aims to validate which diagnostic tests most effectively predict which of the approximately 90% of FDA-approved cancer drugs outside current NCCN Guidelines work for specific patients, producing evidence to enable off-guideline prescriptions and insurance coverage. With no travel required and participation available through any oncologist nationwide, the study seeks to create a scalable method for unlocking access to treatments currently excluded from standard guidelines.PR NewswireBrain Cancer Support and Solutions Alliance Launched to Improve Care and Outcomes for Brain Tumor PatientsHead for the Cure, The Musella Foundation For Brain Tumor Research & Information, and Cancer Commons launched the Brain Cancer Support and Solutions Alliance to improve care and outcomes for brain tumor patients. The alliance will leverage its members' resources to provide support, education, and guidance, starting with the hiring of a neuro-oncology navigator supported by a collaborative grant.PR NewswireRankings Of Most Common And Deadly Cancer Types Will Shift Over Next Two DecadesA study by Cancer Commons and the Pancreatic Cancer Action Network (PanCAN) in collaboration with MD Anderson Cancer Center predicts that pancreatic cancer will become the second leading cause of cancer-related deaths in the U.S. before 2030. The research also projects that melanoma will surpass lung cancer to become the second most common cancer type by 2040, while prostate cancer incidence is expected to decrease significantly due to screening changes.PR NewswirexCures, Inc., together with Cancer Commons and a confidential partner, to launch a virtual medical food trial in patients with pancreatic cancerxCures Inc., together with Cancer Commons and a confidential partner, has launched a medical food clinical trial for patients with advanced pancreatic ductal adenocarcinoma. The prospective, open-label trial will evaluate a highly engineered medical food formulation alongside standard chemotherapy, examining its effects on quality of life, blood measures, and metabolic health over time. This is the first test of this medical food formulation in cancer patients, leveraging xCures' longitudinal registry XCELSIOR to aggregate patient data across the country without requiring patients to switch doctors.PR NewswireDelve Health Joins xCures and Cancer Commons to Support the Beat19 Data Initiative to Conquer COVID-19Delve Health, xCures, and Cancer Commons have partnered to support the Beat19 data initiative, a crowd-sourcing effort to collect global data on COVID-19 impacts. The collaboration aims to engage 100,000 volunteers via a mobile app to map patterns between cancer treatments, behaviors, and coronavirus symptoms. This initiative seeks to identify risk factors and potential modifications for patients with pre-existing chronic conditions.NatureParticipation: Power to the patientsPatient-led data-sharing projects like PatientsLikeMe and Cancer Commons are empowering individuals to contribute genomic and health data, improving research quality and personalized medicine. These initiatives face privacy concerns and unequal benefit distribution, but patient advocacy is seen as essential to overcome barriers in large-scale precision medicine.